Double-Blind, Randomized, Placebo-Controlled Trial of DA-9701 in Parkinson's Disease: PASS-GI Study.

Ji-Hyun ChoiJee-Young LeeJin Whan ChoSeong-Beom KohYoung Soon YangDallah YooCheol-Min ShinHee Tae Kim

Published in: Movement disorders : official journal of the Movement Disorder Society (2020)

DA-9701 therapy improved gastrointestinal symptom-related quality of life, and 12 weeks of daily administration can relieve the overall severity of gastrointestinal symptoms in patients with Parkinson's disease without affecting motor symptoms. (Clinical trial identifier: NCT02775591.) © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keyphrases

double blind
clinical trial
placebo controlled
phase iii
phase ii
study protocol
open label
physical activity
sleep quality
systematic review
bone marrow
smoking cessation